Industry News
Biotechnology Industry News
Neurocrine Biosciences has penned…
Neurocrine Biosciences has penned a deal with China’s TransThera Sciences potentially worth more than $880 million in biobucks for inhibitors aimed at a red-hot inflammation target.
Pfizer has lived up to its threat…
Pfizer has lived up to its threat of taking legal action to prevent Metsera from slipping out of its grasp, but the obesity biotech also seems up for the fight.
Boehringer Ingelheim’s busy year…
Boehringer Ingelheim’s busy year of dealmaking is showing no signs of slowing, with the German pharma now turning to established partner CDR-Life for a new trispecific autoimmune antibody.
Rich Segal highlights the…
Rich Segal highlights the importance of early IPO preparation for companies in the biotech sector and underscores how Chinese biotech companies are increasingly shaping the global biotech landscape.
Neok Bio has exited stealth with…
Neok Bio has exited stealth with $75 million to take a pair of bispecific antibody-drug conjugates sourced from ABL Bio into the clinic.
Welcome to the Fierce Biotech…
Welcome to the Fierce Biotech Graveyard, our annual ritual remembering the biotechs we lost in 2025 and those on the brink.
Nanobiotix is continuing to find…
Nanobiotix is continuing to find fresh ways to eke money out of its Johnson & Johnson-partnered, phase 3-stage cancer drug.
4DMT has sold the Asia-Pacific…
4DMT has sold the Asia-Pacific rights to its eye gene therapy to Otsuka Pharmaceutical, securing $85 million in cash to fund the asset’s phase 3 development.
Gilead has chosen a partner for…
Gilead has chosen a partner for lenacapavir in the race to develop low-frequency treatments for HIV. After comparing two phase 1 integrase strand transfer inhibitors, the Bay Area pharma has elected to pair GS-3242 with
Steven Hatfill, a senior advisor…
Steven Hatfill, a senior advisor for biosecurity at the Department of Health and Human Services, has been terminated from HHS “for cause,” an agency spokesperson confirmed to Fierce Biotech.
Eli Lilly has halted development…
Eli Lilly has halted development of a phase 2 P2X7 inhibitor for pain in the latest shakeup to a pipeline that has already seen significant pivots this year.
Bristol Myers Squibb is shedding…
Bristol Myers Squibb is shedding two clinical programs from its in-house pipeline, one from its 2023 Mirati buyout and another from a partnership with U.K. biotech Exscientia, now known as Recursion.
Inflammation biotech Evommune…
Inflammation biotech Evommune plans to take the leap into public waters with an expected initial public offering price between $15 and $17 per share.
Sensei Biotherapeutics is…
Sensei Biotherapeutics is abandoning its sole clinical-stage drug and warning of imminent layoffs as the company mulls its options.
Takeda has given up on an…
Takeda has given up on an AstraZeneca-partnered neurological disorder program after the therapy flunked a phase 2 study.
Novo Nordisk has thrown a…
Novo Nordisk has thrown a curveball at Pfizer by attempting to outbid the U.S. pharma for the obesity biotech Metsera.
After Intellia Therapeutics paused…
After Intellia Therapeutics paused a pair of phase 3 trials for its CRISPR therapy in response to a liver safety signal, the FDA has made things official by placing the studies under a clinical hold.
Boehringer gave no hint of the…
Boehringer gave no hint of the small molecule’s modality or what indications it will be tested against first.
Roche has headed back to China to…
Roche has headed back to China to pen a licensing deal worth more than $1 billion biobucks for the rights to a clinical-stage bispecific antibody for respiratory diseases.
Roche’s Genentech unit is laying…
Roche’s Genentech unit is laying off staff at its Bay Area headquarters for the third time this year, saying goodbye to 118 employees in a workforce reduction that spans multiple departments.